Moreover, although amyloid and tau CSF biomarkers, amyloid and tau brain PET, and genetic testing for APOE genotype may be available in Latin America, these diagnostic modalities are limited to research settings and are rarely available in the clinical setting, increasing the difficulty in appropriate diagnosis of prodromal AD and AD. This evidence concerns the gene MAPT and Alzheimer disease.